1. Home
  2. SRL vs ADVM Comparison

SRL vs ADVM Comparison

Compare SRL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$6.32

Market Cap

83.0M

ML Signal

HOLD

Logo Adverum Biotechnologies Inc.

ADVM

Adverum Biotechnologies Inc.

HOLD

Current Price

$4.36

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRL
ADVM
Founded
2017
2006
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
94.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SRL
ADVM
Price
$6.32
$4.36
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$11.60
AVG Volume (30 Days)
9.9K
497.5K
Earning Date
12-30-2025
11-12-2025
Dividend Yield
16.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,535,042.00
N/A
Revenue This Year
N/A
$1,192.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$1.78
52 Week High
$9.99
$6.12

Technical Indicators

Market Signals
Indicator
SRL
ADVM
Relative Strength Index (RSI) 59.62 58.20
Support Level $5.85 $4.15
Resistance Level $6.36 $4.23
Average True Range (ATR) 0.43 0.09
MACD 0.05 0.02
Stochastic Oscillator 47.78 95.22

Price Performance

Historical Comparison
SRL
ADVM

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: